Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Daniela Werkmann"'
Autor:
Solveig Skovlund Groen, Dovile Sinkeviciute, Anne-Christine Bay-Jensen, Christian S. Thudium, Morten A. Karsdal, Simon Francis Thomsen, Sven Lindemann, Daniela Werkmann, Joseph Blair, Line Mærsk Staunstrup, Patrik Önnerfjord, Lars Arendt-Nielsen, Signe Holm Nielsen
Publikováno v:
Osteoarthritis and Cartilage Open, Vol 3, Iss 4, Pp 100207- (2021)
Objectives: There is an unmet medical need for biomarkers in OA which can be applied in clinical drug development trials. The present study describes the development of a specific and robust assay measuring type II collagen degradation (T2CM) and dis
Externí odkaz:
https://doaj.org/article/dbead7b88abd48ba819c5601d42f0785
Autor:
Anne Gigout, Daniela Werkmann, Stephanie Menges, Christian Brenneis, Frances Henson, Kyra J. Cowan, Djordje Musil, Christian S. Thudium, Hans Gühring, Martin Michaelis, Kerstin Kleinschmidt‐Doerr
Publikováno v:
Arthritisrheumatology (Hoboken, N.J.)REFERENCES.
To preclinically characterize a mutant form of growth and differentiation factor 5, R399E, with reduced osteogenic properties as a potential disease-modifying osteoarthritis (OA) drug.Cartilage, synovium, and meniscus samples from patients with OA we
Autor:
Benedikte Serruys, Anne Sofie Siebuhr, Christoph Ladel, Christian S. Thudium, M. Michaelis, A.-C. Bay-Jensen, Morten A. Karsdal, Daniela Werkmann, Sven Lindemann
Publikováno v:
International Journal of Molecular Sciences, Vol 21, Iss 5992, p 5992 (2020)
International Journal of Molecular Sciences
Volume 21
Issue 17
International Journal of Molecular Sciences
Volume 21
Issue 17
Osteoarthritis (OA) is associated with cartilage breakdown, brought about by ADAMTS-5 mediated aggrecan degradation followed by MMP-derived aggrecan and type II collagen degradation. We investigated a novel anti-ADAMTS-5 inhibiting Nanobody®
Autor:
Anne-Christine Bay-Jensen, Sven Lindemann, Signe Holm Nielsen, Solveig Skovlund Groen, Dovile Sinkeviciute, Patrik Önnerfjord, Christian S. Thudium, Simon Francis Thomsen, Lars Arendt-Nielsen, Morten A. Karsdal, Line Mærsk Staunstrup, Joseph P.M. Blair, Daniela Werkmann
Publikováno v:
Osteoarthritis and Cartilage Open, Vol 3, Iss 4, Pp 100207-(2021)
Objectives: There is an unmet medical need for biomarkers in OA which can be applied in clinical drug development trials. The present study describes the development of a specific and robust assay measuring type II collagen degradation (T2CM) and dis
Autor:
Anne-Christine Bay-Jensen, Daniela Werkmann, M. Michaelis, Morten A. Karsdal, Thorbjørn Gantzel, Neha Sharma, Sven Lindemann, Christian S. Thudium, Christoph Ladel
Publikováno v:
Abstracts Accepted for Publication.
Background: Patients with joint diseases such as osteoarthritis (OA) are believed to have an abundance of endogenous Toll like receptor (TLR) ligands in their joints, which might be responsible for activating TLRs that may ultimately initiate a self-
Autor:
Klaus Maskos, Christos Tsaklakidis, Daniela Werkmann, Ulrich Grädler, Markus Klein, Birgitta Leuthner, Paul Czodrowski, Sven Lindemann
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 24:4141-4150
We discovered a novel series of non-peptidic acylguanidine inhibitors of Cathepsin D as target for osteoarthritis. The initial HTS-hits were optimized by structure-based design using CatD X-ray structures resulting in single digit nanomolar potency i
Autor:
L. Dejager, Hans Guehring, Christoph Ladel, S. Cornelis, Daniela Werkmann, Sven Lindemann, Marie-Ange Buyse, M.A. Karsdal, Christian S. Thudium, M. Michaelis
Publikováno v:
Osteoarthritis and Cartilage. 26:S178
Autor:
Anne Gigout, Daniela Werkmann, Anne Sofie Siebuhr, A.-C. Bay-Jensen, M.A. Karsdal, T. Mang, Hans Guehring, Christoph Ladel
Publikováno v:
Osteoarthritis and Cartilage. 24:S69-S70